Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Antivir Ther ; 20(1): 49-55, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-24832015

RESUMO

BACKGROUND: Shedding of the pandemic virus during an influenza pandemic is thought to persist longer than shedding of influenza viruses during annual influenza seasons, because people have much less immunity against a pandemic influenza. A correlation is thought to exist between the length of virus shedding and the clinical severity of influenza illness. METHODS: We compared the virus isolation rates of children with pandemic A H1N1/09 influenza infection and children with A H3N2 influenza infection after the patients had been treated with one of three neuraminidase inhibitors (NAI) such as peramivir, laninamivir and oseltamivir. The clinical effectiveness of each NAI was assessed on the basis of the duration of the febrile period after the start of treatment. RESULTS: Influenza viruses were isolated from 15 of the 34 patients in the A H3N2 group (mean age 6.2 years) and from 4 of the 25 patients in the A H1N1/09 (mean age 5.6 years) virus group (44.1% versus 16.0%; P<0.05). However, the differences between the duration of fever in the patients in the A H3N2 group and A H1N1/09 group after treatment with the NAIs were not significant. CONCLUSIONS: The virus isolation rates after treatment with each of the NAIs were significantly lower in the A H1N1/09 group, suggesting that the pandemic A H1N1/09 virus was more sensitive to the NAIs than the seasonal A H3N2 virus was. Clinically, there were no significant differences in the effectiveness of the NAIs between the H1N1/09 infected group and H3N2 infected group.


Assuntos
Antivirais/uso terapêutico , Inibidores Enzimáticos/uso terapêutico , Febre/tratamento farmacológico , Vírus da Influenza A Subtipo H1N1/efeitos dos fármacos , Vírus da Influenza A Subtipo H3N2/efeitos dos fármacos , Influenza Humana/tratamento farmacológico , Ácidos Carbocíclicos , Criança , Pré-Escolar , Ciclopentanos/uso terapêutico , Feminino , Febre/fisiopatologia , Febre/virologia , Guanidinas/uso terapêutico , Humanos , Lactente , Vírus da Influenza A Subtipo H1N1/enzimologia , Vírus da Influenza A Subtipo H1N1/crescimento & desenvolvimento , Vírus da Influenza A Subtipo H1N1/patogenicidade , Vírus da Influenza A Subtipo H3N2/enzimologia , Vírus da Influenza A Subtipo H3N2/crescimento & desenvolvimento , Vírus da Influenza A Subtipo H3N2/patogenicidade , Influenza Humana/fisiopatologia , Influenza Humana/virologia , Masculino , Neuraminidase/antagonistas & inibidores , Neuraminidase/metabolismo , Oseltamivir/uso terapêutico , Piranos , Índice de Gravidade de Doença , Ácidos Siálicos , Fatores de Tempo , Resultado do Tratamento , Proteínas Virais/antagonistas & inibidores , Proteínas Virais/metabolismo , Eliminação de Partículas Virais/efeitos dos fármacos , Zanamivir/análogos & derivados , Zanamivir/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...